NCT07557225Recruiting
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for Tumors Likely to Express High Levels of CAIX
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- 27 Apr 2026
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Peking University First Hospital
- Diseases
- Head and neck cancer, Kidney cancer, Bladder cancer, Endometrial cancer, Cervical cancer, Lung cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Ovarian cancer
- NCT number
- NCT07557225
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 27 Apr 2026 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator.
- Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.
Other
- Participants will be excluded from participation in the study if one or more of the following criteria are met:
- Be a female who is pregnant or breastfeeding.
Who the study is looking for
- All participants must meet the following criteria:
- Written and voluntarily given Informed Consent.
- Male or female ≥18 years of age at time of consent.
- Have the capacity to understand the study and be willing and able to comply with all protocol requirements.
- Participants with histologically confirmed or suspected tumors of the following types, but not limited to:
- Clear Cell Renal Cell Cancer; Urothelial Carcinoma; Colorectal Cancer; Cervical Cancer; Ovarian Cancer; Head and Neck Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Endometrial Cancer; Von Hippel Lindau Disease.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.